Ontology type: schema:ScholarlyArticle
2018-08-31
AUTHORS ABSTRACTAdvances in the understanding of the genetic mechanisms and pathophysiology of neuromuscular diseases have recently led to the development of new, innovative and often mutation-specific therapeutic approaches. Methods used include splicing modification by antisense oligonucleotides, read-through of premature stopcodons, use of viral vectors to introduce genetic information, or optimizing the effectiveness of enzyme replacement therapies. The first drugs have already been approved for the treatment of Duchenne muscular dystrophy and spinal muscular atrophy. For other diseases, such as myotubular myopathy, myotonic dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease, new promising approaches are in preclinical or clinical development. As these are rare diseases with a broad spectrum of clinical severity, drug approval is often based on a limited amount of evidence. Therefore, systematic follow-up in the postmarketing period is particularly important to assess the safety and efficacy of these new and often high-priced orphan drugs. More... »
PAGES1115-1122
http://scigraph.springernature.com/pub.10.1007/s00115-018-0599-9
DOIhttp://dx.doi.org/10.1007/s00115-018-0599-9
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1106468245
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/30171303
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Neurosciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Therapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Genetic Therapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Muscular Atrophy, Spinal",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Muscular Dystrophy, Duchenne",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neuromuscular Diseases",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Oligonucleotides, Antisense",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Klinik f\u00fcr Neurop\u00e4diatrie und Muskelerkrankungen, Medizinische Fakult\u00e4t, Universit\u00e4tsklinikum Freiburg, Mathildenstr.\u00a01, 79106, Freiburg, Deutschland",
"id": "http://www.grid.ac/institutes/grid.492242.b",
"name": [
"Klinik f\u00fcr Neurop\u00e4diatrie und Muskelerkrankungen, Medizinische Fakult\u00e4t, Universit\u00e4tsklinikum Freiburg, Mathildenstr.\u00a01, 79106, Freiburg, Deutschland"
],
"type": "Organization"
},
"familyName": "Kirschner",
"givenName": "J.",
"id": "sg:person.0717435623.02",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717435623.02"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Friedrich-Baur-Institut, Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Deutschland",
"id": "http://www.grid.ac/institutes/grid.5252.0",
"name": [
"Friedrich-Baur-Institut, Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Deutschland"
],
"type": "Organization"
},
"familyName": "Schoser",
"givenName": "B.",
"id": "sg:person.01266531036.43",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266531036.43"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1186/2044-5040-4-12",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019508291",
"https://doi.org/10.1186/2044-5040-4-12"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00112-015-0004-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1018666302",
"https://doi.org/10.1007/s00112-015-0004-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00112-011-2603-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1007819684",
"https://doi.org/10.1007/s00112-011-2603-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nrm1050",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009825202",
"https://doi.org/10.1038/nrm1050"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00415-016-8219-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1024891775",
"https://doi.org/10.1007/s00415-016-8219-8"
],
"type": "CreativeWork"
}
],
"datePublished": "2018-08-31",
"datePublishedReg": "2018-08-31",
"description": "Advances in the understanding of the genetic mechanisms and pathophysiology of neuromuscular diseases have recently led to the development of new, innovative and often mutation-specific therapeutic approaches. Methods used include splicing modification by antisense oligonucleotides, read-through of premature stopcodons, use of viral vectors to introduce genetic information, or optimizing the effectiveness of enzyme replacement therapies. The first drugs have already been approved for the treatment of Duchenne muscular dystrophy and spinal muscular atrophy. For other diseases, such as myotubular myopathy, myotonic dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease, new promising approaches are in preclinical or clinical development. As these are rare diseases with a\u00a0broad spectrum of clinical severity, drug approval is often based on a\u00a0limited amount of evidence. Therefore, systematic follow-up in the postmarketing period is particularly important to assess the safety and efficacy of these new and often high-priced orphan drugs.",
"genre": "article",
"id": "sg:pub.10.1007/s00115-018-0599-9",
"inLanguage": "de",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1018193",
"issn": [
"0028-2804",
"1433-0407"
],
"name": "Der Nervenarzt",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "10",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "89"
}
],
"keywords": [
"muscular dystrophy",
"enzyme replacement therapy",
"spinal muscular atrophy",
"Duchenne muscular dystrophy",
"replacement therapy",
"clinical severity",
"first drug",
"postmarketing period",
"therapeutic approaches",
"rare disease",
"Pompe disease",
"clinical development",
"neuromuscular disease",
"muscular atrophy",
"amount of evidence",
"disease",
"facioscapulohumeral muscular dystrophy",
"drug approval",
"myotonic dystrophy",
"dystrophy",
"viral vectors",
"orphan drugs",
"drugs",
"new promising approach",
"broad spectrum",
"premature stopcodon",
"Erkrankungen",
"pathophysiology",
"atrophy",
"therapy",
"severity",
"efficacy",
"treatment",
"approval",
"genetic mechanisms",
"safety",
"promising approach",
"antisense",
"evidence",
"period",
"development",
"stopcodon",
"mechanism",
"genetic information",
"use",
"advances",
"effectiveness",
"understanding",
"modification",
"approach",
"information",
"amount",
"method",
"vector",
"spectra"
],
"name": "Innovative Therapieans\u00e4tze bei heredit\u00e4ren neuromuskul\u00e4ren Erkrankungen",
"pagination": "1115-1122",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1106468245"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00115-018-0599-9"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"30171303"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00115-018-0599-9",
"https://app.dimensions.ai/details/publication/pub.1106468245"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-10T10:23",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_795.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00115-018-0599-9"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00115-018-0599-9'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00115-018-0599-9'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00115-018-0599-9'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00115-018-0599-9'
This table displays all metadata directly associated to this object as RDF triples.
175 TRIPLES
22 PREDICATES
93 URIs
80 LITERALS
14 BLANK NODES